ADH1A and non-small cell lung carcinoma: Our results preliminarily indicate that gefitinib-resistant NSCLC cells can specifically take up 99mTc-HYNIC-ADH-1 and the uptake capacity is higher than that of drug-sensitive NSCLC cells.